RECRUITINGPhase 2INTERVENTIONAL
Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
About This Trial
To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Who May Be Eligible (Plain English)
Who May Qualify:
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG 0-1
- Charlson Comorbidity Index ≤ 4
- Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
Exclusion - none
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
* ECOG 0-1
* Charlson Comorbidity Index ≤ 4
* Imaging visible disease encompassing \< 50% of the prostate gland and consistent with biopsy findings.
Exclusion - none
Treatments Being Tested
RADIATION
focal brachytherapy boost to SBRT
As above
Locations (2)
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
CHUQ
Québec, Quebec, Canada